Search results
Jaguar Health Announces Submission of Clinical Trial Applications for Crofelemer for the Rare...
Digital Journal· 1 day agoJaguar's novel plant-based prescription drug crofelemer has been granted Orphan Drug Designation by the FDA and the ...
STEALTH BIOTHERAPEUTICS' BARTH SYNDROME NDA RECEIVES PRIORITY REVIEW DESIGNATION
KOIN News 6 Portland· 3 days agoFood and Drug Administration ("FDA") has now determined that its New Drug Application ("NDA") for elamipretide for the treatment of Barth ...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 8 hours agoSoligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an ...
Citius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor Conferences
FOX 4 Kansas City· 7 hours agoCitius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical ...
Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb
WFRV 5 Green Bay· 1 day agoUSA News Group – In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding for President Biden's "Cancer ...
Kite and Arcellx to start Phase 3 trial for myeloma therapy By Investing.com
Investing.com· 20 hours agoREDWOOD CITY, Calif. & SANTA MONICA, Calif. - Kite, a Gilead Company (NASDAQ: GILD), and Arcellx,...
Syndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and...
WTNH-TV New Haven· 2 days agoSyndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an...
Small Business - The Brewton Standard | The Brewton Standard
The Brewton Standard· 4 days agoWebinar, moderated by Cantor Fitzgerald, will be held on Monday, May 13, 2024, at 2:00 p.m. ET Discussion will feature Dr. Michel Michaelides, leading expert in the field of inherited eye disease in adults and children SAN DIEGO, May 06
Nanoscope Therapeutics Announces Presentations in Upcoming ASGCT Annual Meeting and Retina World...
FOX 5 San Diego· 3 days agoDALLAS, May 7, 2024 /PRNewswire/ -- Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for retinal degenerative diseases, today announced that ...